Published in Cancer Cell Int on January 31, 2006
Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol (2010) 2.13
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1.48
Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol (2009) 1.26
Acyl-coenzyme A binding domain containing 3 (ACBD3; PAP7; GCP60): an emerging signaling molecule. Prog Lipid Res (2010) 1.16
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem (2010) 1.14
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res (2010) 0.99
Hydralazine target: from blood vessels to the epigenome. J Transl Med (2006) 0.98
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med (2006) 0.98
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther (2009) 0.97
Brain tumor-related epilepsy. Curr Neuropharmacol (2012) 0.96
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid. J Transl Med (2006) 0.91
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J (2007) 0.87
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis (2009) 0.86
Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget (2014) 0.84
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer (2006) 0.83
Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther (2011) 0.83
Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations. J Mol Model (2011) 0.80
Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. EBioMedicine (2015) 0.80
Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol (2015) 0.80
Recent advances in the search for antiviral agents against human papillomaviruses. Antivir Ther (2007) 0.79
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers. Transl Oncol (2014) 0.79
A reproducible approach to high-throughput biological data acquisition and integration. PeerJ (2015) 0.78
Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy. Neurol Sci (2011) 0.78
A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J (2011) 0.77
Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases. Int J Med Sci (2016) 0.77
Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Exp Ther Med (2011) 0.76
Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics (2016) 0.76
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget (2017) 0.75
The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression. Biomed Res Int (2017) 0.75
Response to hydralazine-valproate in a patient with mycosis fungoides. Case Rep Med (2010) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Transcription of eukaryotic protein-coding genes. Annu Rev Genet (2000) 6.12
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene (2002) 5.96
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2004) 4.20
Recent additions and improvements to the Onto-Tools. Nucleic Acids Res (2005) 3.88
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res (2005) 2.57
Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics (2004) 2.52
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res (2002) 2.37
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res (2004) 2.17
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs (2002) 2.13
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58
Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans (2004) 1.49
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol (2005) 1.45
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res (2001) 1.45
DNA methyltransferase inhibitors-state of the art. Ann Oncol (2002) 1.43
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer (2005) 1.40
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res (2003) 1.38
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res (2003) 1.30
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res (2004) 1.26
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer (2004) 1.25
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer (2005) 1.24
Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res (2001) 1.23
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer (2005) 1.14
Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer (2003) 1.04
Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (2003) 1.03
Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol (2005) 1.01
Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol (2005) 0.92
Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res (2001) 0.91
Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Updat (2004) 0.84
2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer (1993) 0.83